Navigation Links
Adnexus Therapeutics Announces Presentation at the American,Association for Cancer Research (AACR) on Clinical Product,Candidate, CT-322

ntrols its patented PROfusion protein design engine. Adnexus has over 100 issued and pending patent properties relating to Adnectins and PROfusion.

About Adnexus Therapeutics

Adnexus Therapeutics is focused on generating vital medicines through the discovery, development, and commercialization of its broadly applicable new therapeutic class, Adnectins. Adnexus' lead product candidate, CT-322, is in Phase 1 clinical development in oncology in the United States. The company also has a pipeline of other Adnectin products in preclinical research across multiple therapeutic areas. Adnectins are designed and optimized using PROfusion, the company's patented protein design engine that uniquely enables rapid optimization of protein therapeutics. The company is funded by four leading venture capital firms: Atlas Venture, Flagship Ventures, Polaris Venture Partners, and Venrock Associates.

This news release contains certain forward-looking statements that involve risks and uncertainties. Such statements are only predictions and the company's actual results may differ materially from those anticipated in these forward-looking statements. Factors that may cause such differences include the timing of clinical trials, the risk that products that appeared promising in early research and clinical trials do not demonstrate safety or efficacy in clinical trials and the risk that the company will not obtain approval to market its products.

Adnectin(TM), Adnexus(TM) Therapeutics and PROfusion(TM) are trademarks of Adnexus(TM) Therapeutics, Inc. Adnexus(SM) Therapeutics is a service mark of Adnexus(TM) Therapeutics.

For more information, please visit www.adnexustx.com

Contact

Corporate Contacts
Adnexus Therapeutics, Inc.
Katrine Bosley, 781-891-3745
Vice President Business Development
pr@adnexustx.com
or
Media Contacts

'"/>




Page: 1 2 3 4

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
5. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
6. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
7. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
8. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
9. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
10. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
11. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care

Post Your Comments:
(Date:11/6/2009)...e-FirstCall/ -- Oxygen Biotherapeutics, Inc. (OTC ...ously approved reverse split of its common stock w... Nov. 9, 2009 on a 1-for-15 split-adjusted basis. ...er the new symbol OXBT. The stock also will have a...omes effective. ,, "This reverse split was over...
(Date:11/6/2009)...wswire-FirstCall/ -- DUSA Pharmaceuticals, Inc.(&#...t is developing and marketing Levulan(®) Phot...on patients with common skin conditions, announced...icer, will present a corporate overview at the Mer... November 10, 2009 at 10:00 a.m. ET at the Hotel S...
(Date:11/6/2009)...wire/ -- Kaiser Foundation Health Plan, Inc., Kais...iaries reported today a combined total operating r...ember 30, 2009, compared to $10.2 billion in the t... third quarter was $336 million, compared to $307 ...-operating income was $233 million in the third qu...
Breaking Medicine Technology:Oxygen Biotherapeutics, Inc. Announces 1:15 Reverse Stock Split to Take Effect Nov. 9, 2009 2Oxygen Biotherapeutics, Inc. Announces 1:15 Reverse Stock Split to Take Effect Nov. 9, 2009 3Kaiser Foundation Health Plan and Hospitals Report Third Quarter 2009 Financial Results 2Kaiser Foundation Health Plan and Hospitals Report Third Quarter 2009 Financial Results 3Kaiser Foundation Health Plan and Hospitals Report Third Quarter 2009 Financial Results 4Toronto Conference Targets the Vitamin D Deficiency Crisis 60448 1Toronto Conference Targets the Vitamin D Deficiency Crisis 60448 2Toronto Conference Targets the Vitamin D Deficiency Crisis 60448 3BYETTA Approved for Expanded Use as First Line Treatment for Type 2 Diabetes 14673 1BYETTA Approved for Expanded Use as First Line Treatment for Type 2 Diabetes 14673 2BYETTA Approved for Expanded Use as First Line Treatment for Type 2 Diabetes 14673 3BYETTA Approved for Expanded Use as First Line Treatment for Type 2 Diabetes 14673 4BYETTA Approved for Expanded Use as First Line Treatment for Type 2 Diabetes 14673 5BYETTA Approved for Expanded Use as First Line Treatment for Type 2 Diabetes 14673 6BYETTA Approved for Expanded Use as First Line Treatment for Type 2 Diabetes 14673 7OMG Announces Special Event 3A Terminology Services Information Day 60441 1OMG Announces Special Event 3A Terminology Services Information Day 60441 2OMG Announces Special Event 3A Terminology Services Information Day 60441 3
...er Concordance Compared to FISH and... Include Reporting for HER2 Gene Expression in All... of 2008 -, REDWOOD CITY, Calif., Sept. 6 Genomi...ults from two studies demonstrating,that quantitat...d by the,company,s Oncotype DX(R) breast cancer as...
...Amex: CVM ) announced today that it presented new...ference on Immunogenicity in Amsterdam. The data,p...ident of Research,Cellular Immunology of CEL-SCI, ...ne CEL-2000 prevents or retards the permanent tiss...mal model of the disease. These new,findings furth...
Other Medicine Technology:Genomic Health Announces Data Supporting Use of Oncotype DX(R) to Accurately Assess HER2 Gene Expression in Breast Cancer Patients 2Genomic Health Announces Data Supporting Use of Oncotype DX(R) to Accurately Assess HER2 Gene Expression in Breast Cancer Patients 3Genomic Health Announces Data Supporting Use of Oncotype DX(R) to Accurately Assess HER2 Gene Expression in Breast Cancer Patients 4Genomic Health Announces Data Supporting Use of Oncotype DX(R) to Accurately Assess HER2 Gene Expression in Breast Cancer Patients 5Data Suggest CEL-SCI's CEL-2000 Vaccine Prevents or Retards Permanent Damage of Rheumatoid Arthritis 2Data Suggest CEL-SCI's CEL-2000 Vaccine Prevents or Retards Permanent Damage of Rheumatoid Arthritis 3Data Suggest CEL-SCI's CEL-2000 Vaccine Prevents or Retards Permanent Damage of Rheumatoid Arthritis 4
(Date:11/8/2009)...h Care Reform Bill ,, Critical legislation wo...Americans ,, CHICAGO, Nov. 7 /PRNewswire-USNew...entatives passed by a vote of 220-215, critical he... Medicare for seniors and end discrimination by in...s out of affordable health coverage. ,, The A...
(Date:11/7/2009)...swire/ -- Karen Ignagni, President and CEO of Amer...following statement today on House passage of H.R....hensive health care reform, and we have contribute...aul of how health insurance is provided. Earlier t...tion of pre-existing condition exclusions, no long...
(Date:11/7/2009)... Cook (GA), Louis J. Goodman (TX), Palmer P. Jones..., Nov. 7 The American M...cal society executive leaders with achievement awa...ideals of the medical profession. The awards were ...eeting in Houston. ,, (Logo: http://www.news...
(Date:11/7/2009)...responsibility to vigorously oppose abortion in he...ASHINGTON, Nov. 7 Am...the following statement on the news that Cardinal ...Affordable Health Care for America Act (H.R. 3962)...for abortion is voted upon. ,, "Our Catholic b...
(Date:11/7/2009)...ciety of America (PRSA) will bestow the distinguis...vice president of Brand Strategy, Communications a... at PRSA,s 2009 International Conference in San Di... Fellows is one of the profession,s highest indivi...ow PRSA, and 2009 chair of the College of Fellows....
Breaking Medicine News(10 mins):Health News:AARP Illinois Key Vote News Alert 2Health News:AARP Illinois Key Vote News Alert 3Health News:AHIP Statement on House Passage of H.R. 3962 2Health News:AMA Honors Medical Society Executives 2Health News:Statement Regarding Cardinal Rigali's Memo Protecting the 'Status Quo' On Life 2Health News:PRSA Inducts Head of Public Relations for Kaiser Permanente Into the College of Fellows for Contributions to the Profession and Lifetime Achievement 2Health News:PRSA Inducts Head of Public Relations for Kaiser Permanente Into the College of Fellows for Contributions to the Profession and Lifetime Achievement 3
...y,s Feinberg School of Medicine has been awarded a... Health for a landmark national research, clinical...ats posed to women by cancer treatment. , When a ...r sends it into remission can destroy a woman,s ab...
...pkins, University of California San, Francisco, ...Profiling, COLUMBIA, S.C., Sept. 6 Collexis (OTC...owledge management (KM),and discovery software, ha...inguished Collexis clients including,Johns Hopkins...
...parents and guardians include child ...rk., Sept. 6 Keeping kids,healthy and safe is a p...ng,the right tips and tools for every stage of a c...ited Children (NCMEC),to host "Baby Days," complim...
...troit Free Press,incorrectly reported that Blue Cr...eneric Prilosec(R) and said it was the first time ...Blue Cross Blue Shield of Michigan has had an awar...er 5, the company did announce that it was paying ...
...porosis Foundation (NOF) has teamed up with Ladies... starting September 8th and culminating on,October...duals across the,country to Start Right, Stay Stro...evention, diagnosis and treatment., Each Start Ri...
...rt Card Provides Information on NY/NJ HMO Qual...LAKE SUCCESS, N.Y., Sept. 6 Health care consumers...nique new tool for evaluating,the region,s hospita...ides data on the cost and quality of care,received...
Other Medicine News:Health News:Don't just save her life, save her fertility 2Health News:Don't just save her life, save her fertility 3Health News:Don't just save her life, save her fertility 4Health News:Don't just save her life, save her fertility 5Health News:Don't just save her life, save her fertility 6Health News:Mayo Clinic to Pilot Collexis' Expert Profiling 2Health News:Mayo Clinic to Pilot Collexis' Expert Profiling 3Health News:The National Center for Missing & Exploited Children, Wal-Mart, and Abbott Host Child Safety Events 2Health News:The National Center for Missing & Exploited Children, Wal-Mart, and Abbott Host Child Safety Events 3Health News:The National Center for Missing & Exploited Children, Wal-Mart, and Abbott Host Child Safety Events 4Health News:Blue Cross Blue Shield of Michigan Corrects News Story about Drug Coverage Announcement 2Health News:National Osteoporosis Foundation Teams Up With Ladies Home Journal Magazine to Launch a 10-city Mall Walk Tour 2Health News:First New York/New Jersey Health Care Report Card Released 2Health News:First New York/New Jersey Health Care Report Card Released 3Health News:First New York/New Jersey Health Care Report Card Released 4Health News:First New York/New Jersey Health Care Report Card Released 5
Gellhorn Pessary
Ring Pessary
Pyramis
...female urinary stress incontinence (SUI) with a mi...ic (BioArcTM SP) or a transobturator (BioArcTM TO)...em combining synthetic and biologic materials. It ...BioArc utilizes a polypropylene mesh for fixation ...
Medicine Products: